A try to ink "super blood"
Super blood
A Cambridge, Massachusetts-based biotech firm Rubius Therapeutics has secured funding totaling about 200 million USD in its quest to develop breakthrough treatment options. Earlier, it raised 120 million USD in June 2017.
The game-changing tech venture aims to address the issue of immune disorder and enzymes deficiency using Red Blood Cells as therapy option.
According to CEO Torben Straight Nissen, the initiative will pave way for 'super blood' which upon infusion to the human body will cleanse it of maladies.
Gene Therapies
US Food and Drug Administration has approved two gene therapies to treat cancer cells. However, the solution promised by Rubius Therapeutics offer quicker, cheaper and more feasible curative option.
According to sciencecare.com, gene disorders are responsible for about 4,000 medical conditions. Any positive revolutionary twist in this arena can widen treatment options for a variety of diseases.